公开(公告)号：US20240383947A1

公开(公告)日：2024-11-21

申请号：US18287608

申请日：2022-04-20

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Alexander Muik

IPC: C07K14/005 ,  A61K39/00 ,  A61K39/215 ,  A61K39/295 ,  A61P37/04

Abstract: This disclosure relates to the field of preventing or treating virus infection, in particular, the disclosure relates to agents for vaccination against virus infection and inducing effective virus antigen-specific immune responses such as antibody and/or T cell responses and methods for generating and using such agents. Administration of agents such as RNA disclosed herein to a subject can protect the subject against virus infection. Specifically, the present disclosure relates to amino acid sequences comprising at least a portion of a virus protein having amino acid modifications found in other variants of the virus protein. Administration of RNA encoding one or more of the amino acid sequences may provide protection against diverse virus variants. Methods and agents described herein are, in particular, useful for the prevention or treatment of coronavirus infection such as SARS-CoV-2 infection.

公开(公告)号：US20240339174A1

公开(公告)日：2024-10-10

申请号：US18289425

申请日：2022-05-04

Applicant: BioNTech SE ,  InstaDeep Ltd.

Inventor： Alexander Muik ,  Asaf Poran ,  Yunpeng Liu ,  Ugur Sahin ,  Karim Beguir ,  Marcin Skwark ,  Thomas Pierrot ,  Yunguan Fu

IPC: G16B20/20 ,  C07K14/005 ,  G16B15/30 ,  G16B40/20

CPC classification number: G16B20/20 ,  C07K14/005 ,  G16B15/30 ,  G16B40/20 ,  C12N2770/20022

Abstract: The present disclosure provides technologies for identifying, characterizing, and/or monitoring sequences of a variant of a reference infectious agent (e.g., but not limited to viral variants, for example in some embodiments SARS-CoV-2 variants) for transmissibility factors and/or immune escape potential, and/or for detecting and/or monitoring variants in environmental or biological samples, and/or for designing, preparing, and/or administering vaccines for such variants.

公开(公告)号：US20240042011A1

公开(公告)日：2024-02-08

申请号：US18186914

申请日：2023-03-20

Applicant: BioNTech SE

Inventor： Alexander Muik ,  Asaf Poran ,  Kena Anne Swanson ,  Qi Yang ,  Hui Cai ,  Ugur Sahin

IPC: A61K39/215 ,  A61K39/145 ,  A61K9/127 ,  A61K47/26 ,  C12N15/86

CPC classification number: A61K39/215 ,  A61K39/145 ,  A61K2039/545 ,  A61K47/26 ,  C12N15/86 ,  A61K9/1272

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

公开(公告)号：US20230330198A1

公开(公告)日：2023-10-19

申请号：US18333273

申请日：2023-06-12

Applicant: BioNTech SE ,  TRON - Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz

Inventor： Ugur Sahin ,  Sebastian Kreiter ,  Christina Krienke ,  Jutta Petschenka ,  Lena Mareen Kranz ,  Mustafa Diken

IPC: A61K39/00 ,  A61P37/06 ,  C12N15/11 ,  C12N15/117

CPC classification number: A61K39/0008 ,  A61P37/06 ,  C12N15/11 ,  C12N15/117 ,  A61K2039/53 ,  A61K2039/55555 ,  C12N2310/335

Abstract: The present invention relates to non-immunogenic RNA. This RNA forms the basis for the development of therapeutic agents for inducing tolerance towards an autoantigen and thus, for the treatment of autoimmune diseases.

公开(公告)号：US20230272406A1

公开(公告)日：2023-08-31

申请号：US17936377

申请日：2022-09-28

Applicant: BioNTech SE ,  TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gG

Inventor： Alexandra Orlandini Von Niessen ,  Stephanie Fesser ,  Britta Vallazza ,  Tim Beissert ,  Andreas Kuhn ,  Ugur Sahin ,  Marco Alexander Poleganov

IPC: C12N15/67 ,  A47B3/00 ,  A47B13/02 ,  A47B33/00 ,  A47B43/00 ,  A47B77/02 ,  A47B77/06 ,  A47B77/08 ,  A47B77/16 ,  A47B77/18 ,  A47B95/00 ,  A47C4/00 ,  A47C4/08 ,  A47C7/00 ,  A47K3/28 ,  B60B33/00 ,  E04H1/12 ,  F16C11/04 ,  C12N5/0735 ,  C12N15/113 ,  C12N15/90

CPC classification number: C12N15/67 ,  A47B3/002 ,  A47B13/02 ,  A47B33/00 ,  A47B43/00 ,  A47B77/022 ,  A47B77/06 ,  A47B77/08 ,  A47B77/16 ,  A47B77/18 ,  A47B95/00 ,  A47B95/008 ,  A47C4/00 ,  A47C4/08 ,  A47C7/002 ,  A47C7/006 ,  A47K3/284 ,  B60B33/00 ,  E04H1/1266 ,  F16C11/04 ,  C12N5/0606 ,  C12N15/113 ,  C12N15/90 ,  A47B2003/006 ,  A47B2200/0018 ,  C12N2310/113

Abstract: The present invention relates to stabilization of RNA, in particular mRNA, and an increase in mRNA translation. The present invention particularly relates to a modification of RNA, in particular in vitro-transcribed RNA, resulting in increased transcript stability and/or translation efficiency. According to the invention, it was demonstrated that certain sequences in the 3′-untranslated region (UTR) of an RNA molecule improve stability and translation efficiency.

公开(公告)号：US11222711B2

公开(公告)日：2022-01-11

申请号：US14787110

申请日：2014-05-07

Applicant: BioNTech SE ,  TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG—UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH

Inventor： Ugur Sahin ,  Arbel David Tadmor ,  John Christopher Castle ,  Sebastian Boegel ,  Martin Löwer

IPC: G16B20/20 ,  G16B20/00 ,  A61K39/00 ,  C12Q1/6886

Abstract: The present invention relates to methods for predicting T cell epitopes. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic or not. The methods of the invention are useful, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.

公开(公告)号：US12208136B2

公开(公告)日：2025-01-28

申请号：US18186914

申请日：2023-03-20

Applicant: BioNTech SE

Inventor： Alexander Muik ,  Kena Anne Swanson ,  Qi Yang ,  Hui Cai ,  Ugur Sahin ,  Kayvon Modjarrad

IPC: A61K39/215 ,  A61K9/127 ,  A61K39/145 ,  A61K45/06 ,  A61K47/26 ,  C12N15/86 ,  A61K39/00

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

公开(公告)号：US20250027066A1

公开(公告)日：2025-01-23

申请号：US18708333

申请日：2022-11-09

Applicant: BIONTECH SE

Inventor： Ugur Sahin ,  Andreas Henning ,  Stephanie Erbar ,  Stefan Albrecht Schille ,  Anna Spier ,  Lorenzo Corsini ,  Zehra Visram

IPC: C12N9/36 ,  A61K9/00 ,  A61K9/51 ,  A61P31/04

Abstract: The invention provides agents and methods for treating bacterial infections using RNA. The RNA encoding peptidoglycan hydrolases. e.g., endolysins, is formulated and administered in a way that peptidoglycan hydrolase proteins. e.g., endolysin proteins, can be produced and secreted by cells of a subject to combat bacterial infections.

公开(公告)号：US12150947B2

公开(公告)日：2024-11-26

申请号：US16957898

申请日：2019-01-10

Applicant: BioNTech SE ,  TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GGMBH

Inventor： Ugur Sahin ,  Heinrich Haas ,  Annette Vogel ,  Stephanie Erbar ,  Kerstin Walzer ,  Anne Schlegel ,  Sebastian Hörner ,  Jorge Herrero Moreno ,  Thorsten Klamp ,  Sebastian Kreiter ,  Mustafa Diken ,  Phillip Heller

IPC: A61K31/70 ,  A61K9/00 ,  A61K35/763 ,  A61K47/18

Abstract: The present invention relates to compositions comprising polyplex formulations for delivery of RNA to a target organ or a target cell after parenteral administration, in particular after intramuscular administration. More precisely, the present invention relates to formulations for administration of RNA such as self-replicating RNA, in particular by intramuscular injection. In more detail, the formulations comprise polyplex particles from single stranded RNA and a polyalkyleneimine.

公开(公告)号：US12054723B2

公开(公告)日：2024-08-06

申请号：US16898176

申请日：2020-06-10

Applicant: BioNTech SE ,  TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg—Universität Mainz gG

Inventor： Florian Eberle ,  Ugur Sahin ,  Andreas Kuhn ,  Britta Vallazza ,  Mustafa Diken

IPC: C12N5/00 ,  A61K39/00 ,  A61K48/00 ,  C12N15/67 ,  C12N15/68 ,  C12N15/70 ,  C12N15/85 ,  C12P19/34 ,  C12P21/00

CPC classification number: C12N15/68 ,  A61K39/00 ,  A61K48/0066 ,  C12N15/67 ,  C12N15/70 ,  C12N15/85 ,  C12P19/34 ,  C12P21/00 ,  A61K2039/53 ,  C12N2830/50

Abstract: The present invention relates to nucleic acid molecules containing poly (dA:dT) regions which are stabilized in E.-coli, methods of propagating such nucleic acid molecules in E. coli, methods of obtaining RNA, peptides or proteins using such nucleic acid molecules and to RNA which is obtained from such nucleic acid molecules and its use. In particular, the poly (dA:dT) regions contain at least one disruption by a sequence not encoding a sequence solely composed of A residues.